Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | FABP3 | P05413 | 3/20 | 0.42 |
| ▸ | FABP4 | P15090 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131834 | 1.00 | PTPN1 (0.46) | PTPN1PTPN2CDC25BNR1H4FABP3 | |
| SCHEMBL1131586 | 0.90 | FABP3 (0.45) | PTPN1FABP3FABP4MDM2CMKLR1 | |
| SCHEMBL1131282 | 0.90 | FABP3 (0.45) | PTPN1FABP3FABP4MDM2CMKLR1 | |
| SCHEMBL1132020 | 0.86 | PTGS2 (0.42) | FABP3FABP4ALDH1A1CMKLR1 | |
| SCHEMBL1132017 | 0.86 | PTGS2 (0.42) | FABP3FABP4ALDH1A1CMKLR1 | |
| SCHEMBL1131572 | 0.85 | HRH3 (0.45) | FABP3FABP4ALDH1A1MDM2CMKLR1 | |
| SCHEMBL1131946 | 0.82 | FAAH (0.54) | FABP3FABP4MDM2CMKLR1L3MBTL1 | |
| SCHEMBL1131367 | 0.82 | FAAH (0.37) | NR1H4FABP3FABP4CMKLR1 | |
| SCHEMBL1131371 | 0.82 | FAAH (0.37) | NR1H4FABP3FABP4CMKLR1 | |
| SCHEMBL1131692 | 0.82 | PTPN1 (0.48) | PTPN1PTPN2CDC25BNR1H4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | claimed |
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | disclosed |